<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="740">
  <stage>Registered</stage>
  <submitdate>15/09/2005</submitdate>
  <approvaldate>26/09/2005</approvaldate>
  <actrnumber>ACTRN12605000507684</actrnumber>
  <trial_identification>
    <studytitle>Can routine N-of-1 studies improve net benefits and reduce costs by better targeting chronic therapy?</studytitle>
    <scientifictitle>Can routine N-of-1 studies improve net benefits and reduce costs by better targeting chronic therapy for Attention Deficit Hyperactivity Disorder?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Attention Deficit Hyperactivity Disorder.</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This single patient (n of 1) trial is a randomised, double-blind, cross-over comparison of methylphenidate and placebo within an individual patient.  The patient will undergo three pairs of treatment periods.  The order of treatment in each cycle will be determined by random allocation.  The choice of initial therapy will be balanced in blocks of four, to ensure that equivalent numbers start the IMET on each of the two medications.  Patients, parents and practitioners will all be blinded to which treatment the patients are taking.  Product information will be provided to the patient and parent at the beginning of the study.

Parents, teachers, and patients over 12 years will complete ADHD Rating Scales at the end of two days (or one week for the 6 week IMET). If at any time during the study the patient feels worse, that treatment period can be terminated, and they can go on to the next treatment period.

Upon completion of the study, the timing of the active treatment will be revealed.  After looking at the symptoms recorded, the doctor and patient decide together whether methylphenidate is of significant benefit.  If the patient chooses, they can then continue on that medication, confident that it is effective for them.</interventions>
    <comparator>Placebo</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To improve therapeutic decision making about Attention Deficit Hyperactivity Disorder (ADHD) medications, by educating the doctor and the patient in the use of Individualised Medication Effectiveness Test methodology for objective individual patient decision making</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate individual patient responses to stimulants in terms of relief of ADHD symptoms, and immediate side-effect profile.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Any school age patient with a clinical diagnosis of ADHD of at least a month's duration, made by a medical practitioner, and who is stabilised on treatment with the stimulant. Patient, parent and doctor would like to use the Individualised Medication Effectiveness Test methodology to see if the patient is a responder to the stimulant.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>19</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Symptomatic cardiovascular disease. Moderate to severe hypertension. Hyperthyroidism. Phaeochromocytoma. Glaucoma. Agitated states. Anxiety. Motor tics. Tourette syndrome. MAOIs (+/- 14 days). Idiosyncratic reaction to sympathomimetic amines. History of drug abuse.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>7/08/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>108</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Queensland</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian Health Ministers' Advisory Council</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Mater Health Services, Brisbane</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Mater Health Services, Brisbane</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Queensland</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Health Services</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Port Kembla Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Margaret Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Children's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Geoff Mitchell</name>
      <address>School of Medicine
University of Queensland
Herston Rd
Herston QLD 4006</address>
      <phone>+61 7 33655504</phone>
      <fax>+61 7 33655130</fax>
      <email>g.mitchell@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Norma McNairn</name>
      <address>Individualised Medication Effectiveness Test (IMET) Service
University of Queensland
Level 2 Edith Cavell Building
Herston QLD 4006</address>
      <phone>+61 7 33464835</phone>
      <fax>+61 7 33655130</fax>
      <email>n.mcnairn@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>